Checkpoint Inhibitor Deals: Searching For IO Combinations To Unlock Cancer’s Black Box

Merck and Bristol-Myers Squibb's market-dominating checkpoint inhibitors are competing to find the next combination therapy to treat more cancer patients, in more types of cancers. Recent failures and new regulatory pressure, however, may have a cooling effect, even as researchers come full circle with PD-l/PD-L1 and CTL-4 combinations. The race is also on to pull new combinations from emerging cell therapy and precision oncology drug candidates.

IV2003_Checkpoint inhibitors_642118657_1200.jpg
3D RENDERING OF PEMBROLIZUMAB MONOCLONAL ANTIBODY • Source: Shutterstock

Immunotherapy treatments for cancer, and the potential synergistic effects of combining established PD-1/PD-L1 checkpoint inhibitors with other experimental candidates and mechanisms, will continue to drive oncology deal-making in 2020. As of November 2019, there were 2,251 active PD-1/PD-L1 combination therapy trials testing 295 different targets, according to the Cancer Research Institute, a non-profit that supports research and development of immunotherapy treatments for cancer. Clinical successes, however, have slowed from the heady days of the early and mid-2000s, when it seemed as though checkpoint inhibitors might become the cancer cures patients and pharmaceutical companies hoped would beat back the disease once and for all.

Almost 10 years have passed since the initial FDA approval of Bristol-Myers Squibb Co.’s cancer drug Yervoy (ipilipumab), an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.